Stock TBPH THERAVANCE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
9.46 USD +1.18% Intraday chart for Theravance Biopharma, Inc. +3.73% -15.84%
04-12 Sector Update: Health Care Stocks Lower Friday Afternoon MT
04-12 Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
PR
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
PR
Theravance Bio: Q4 Earnings Snapshot
AQ
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PR
Theravance Biopharma to Participate in an Upcoming Investor Conference
PR
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
PR
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
PR
Theravance Biopharma : Material Event - Form 8-K
PU
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
PR
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
PR
THERAVANCE BIOPHARMA TO PRESENT NEW AMPRELOXETINE DATA AT THE 34TH INTERNATIONAL SYMPOSIUM ON THE AUTONOMIC NERVOUS SYSTEM
AQ
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PR
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease
AQ
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR
Theravance Bio: Q3 Earnings Snapshot
AQ
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
PR
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
PR
Theravance Biopharma to Participate in an Upcoming Investor Conference
PR
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
PR
Theravance Bio: Q2 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TBPH Stock
  4. News Theravance Biopharma, Inc.
  5. Press Releases